Enzymatica today presents for the first time to Swedish doctors the final report from the German multicenter study that evaluated ColdZyme® for treatment of the common cold at the Ear-Nose-and-Throat Days conference in Malmö. The final report confirms earlier preliminary favorable results from the use of ColdZyme, compared with the group that was not treated. Based on the convincing results, Enzymatica has been able to expand the product claims for ColdZyme.
The statistically significant results from the study confirm the earlier product claim that ColdZyme can reduce the duration of colds when used at an early stage of infection and make it possible to add the new product claims that ColdZyme alleviates common cold symptoms and soothes sore throat, improves quality of life, and reduces concurrent use of symptom-relieving drugs.
The single-blind, prospective, randomized controlled multicenter study was carried out at six centers in Germany during the 2018 cold season. The study included 400 participants who were randomly asked either to initiate treatment with ColdZyme at the first cold symptoms, or to refrain from any treatment. A total of 267 individuals with confirmed colds were included and assessed in the study.
The study results show a significant reduction of both duration of colds and intensity of symptoms, as well as reduced use of symptom-relieving drugs when using ColdZyme, compared with a control group that did not use ColdZyme.
“The extremely convincing study results enable us to broaden the product claims for ColdZyme, especially regarding improved quality of life. The results have also served as the foundation for the design of the currently ongoing double-blind, placebo-controlled study to evaluate the effects of ColdZyme on the common cold. This extensive study includes more than 600 patients at ten study centers in Germany and is expected to be completed during the second half of 2019,” says Fredrik Lindberg, CEO of Enzymatica.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: firstname.lastname@example.org
Carl-Johan Wachtmeister, Head of Corporate Communications, Enzymatica AB
Tel: +46 (0)701-88 50 21 | Email: email@example.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company’s first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit:www.enzymatica.com.
Enzymatica’s Certified Adviser is Erik Penser Bank.
Tel: +46 (0)8-463 83 00